Cortes et al. compared the efficacy of quizartinib, an oral selective type II FLT3 inhibitor, with that of salvage chemotherapy in patients with relapsed or refractory FLT3-ITD acute myeloid leukemia. Here, FLT3 is linked to acute myeloid leukemia.